← InflaRx N.V. (IFRX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
InflaRx N.V. (IFRX)
Pharmaceutical Preparations · market cap $300M · as of 2026-07-10
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-09 (est.)
Earnings
Pipeline
7
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
InflaRx N.V. (IFRX) is a small-cap clinical-stage pharmaceutical company with 74 employees and a ~$280M market cap trading near $2.16. Its lead asset IFX-1 (vilobelimab) is in Phase 3 for Severe COVID-19 Pneumonia, with a broader pipeline spanning Phase 2 programs in Pyoderma Gangrenosum, Hidradenitis Suppurativa, Granulomatosis With Polyangiitis, and Severe Sepsis. The company faces elevated dilution risk (24% over the past year) and no disclosed cash runway, making financing a central concern.
The catalyst path
- 2026-11-09 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| IFX-1 + BSC | Phase 3 | Severe COVID-19 Pneumonia |
| vilobelimab | Phase 2 | Pyoderma Gangrenosum |
| Glucocorticoid (GC) | Phase 2 | Granulomatosis With Polyangiitis (GPA) |
| CaCP29 | Phase 2 | Severe Sepsis |
| IFX-1 | Phase 2 | Hidradenitis Suppurativa |
| Cohort A: vilobelimab | Phase 2 | Acute Respiratory Distress Syndrome (ARDS) |
| Cohort B: paridiprubart | Phase 2 | Acute Respiratory Distress Syndrome (ARDS) |
Price & technical context
3-month
-23.7%
6-month
+90.0%
12-month
+27.6%
52-wk range
$0.82–$2.74
vs 50-day MA
-14.2%
vs 200-day MA
+8.0%
Realized vol
94.6%
Max drawdown
-73.0%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for IFRX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 7 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.